who we are

Angion is a late-stage biopharmaceutical company focused on
the discovery, development, and commercialization of novel
small molecule therapeutics to address acute organ injuries and
fibrotic diseases.

clinical trials

If you wish to learn more about enrolling in our Phase 3 trial studying the safety and efficacy of ANG-3777

OUR LEAD CLINICAL ASSET

ANG-3777

is engineered to activate the HGF/c-MET pathway,
an important mechanism in organ repair.

THE SCIENCE BEHIND

ANG-3777

ANG-3777 is a small molecule designed to mimic the biological activity of HGF, thereby activating the c-Met cascade of pathways involved in tissue repair and organ recovery. ANG-3777 has demonstrated several similarities to HGF, including c-Met dependence and selective c-Met receptor activation, without acting on other growth factor receptors. In addition, it has a substantially longer half-life than HGF. *

*ANG-3777 is currently being studied in clinical trials to determine if it is safe and effective. It is not yet approved for use by any regulatory agency globally.